POLARIS NN9490-8266
Efficacy and safety of amycretin on morbidity and mortality compared to placebo in people with heartfailure with preserved or mildly reduced ejection fraction and obesity.
- Stage
- inclusie
- Medicine
- Amycretin
- Population
- Hartfalen
- Phase
- III
- First Patient In
- 11 May 2026
- Last Patient In
- 21 April 2028
- Last Patient Last Visit
- 22 June 2029
Inclusion period, 711 days remaining
National Lead
Meems
Study Director
dr. S. Koudstaal
Cardioloog
Office Contact
